# EDGAR Filing Document

**Accession Number:** 0001496323
**File Stem:** 0001193125-25-180427
**Filing Date:** 2025-8
**Character Count:** 8345
**Document Hash:** 2aaad9fcb80a1e548e006d82fb1e3947
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-180427.hdr.sgml**: 20250814

**ACCESSION NUMBER**: 0001193125-25-180427

**CONFORMED SUBMISSION TYPE**: SC 14D9/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250814

**DATE AS OF CHANGE**: 20250814

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IGM Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001496323
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 770349194
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 14D9/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91132
- **FILM NUMBER:** 251214776

**BUSINESS ADDRESS:**
- **STREET 1:** 325 E MIDDLEFIELD ROAD
- **CITY:** MOUNTAIN VIEW
- **STATE:** CA
- **ZIP:** 94043
- **BUSINESS PHONE:** 650-965-7873

**MAIL ADDRESS:**
- **STREET 1:** 325 E MIDDLEFIELD ROAD
- **CITY:** MOUNTAIN VIEW
- **STATE:** CA
- **ZIP:** 94043

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Palingen, Inc.
- **DATE OF NAME CHANGE:** 20100712
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IGM Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001496323
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 770349194
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 14D9/A

**BUSINESS ADDRESS:**
- **STREET 1:** 325 E MIDDLEFIELD ROAD
- **CITY:** MOUNTAIN VIEW
- **STATE:** CA
- **ZIP:** 94043
- **BUSINESS PHONE:** 650-965-7873

**MAIL ADDRESS:**
- **STREET 1:** 325 E MIDDLEFIELD ROAD
- **CITY:** MOUNTAIN VIEW
- **STATE:** CA
- **ZIP:** 94043

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Palingen, Inc.
- **DATE OF NAME CHANGE:** 20100712

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE 14D-9** 

**Solicitation/Recommendation Statement** 

**Under Section 14(d)(4) of the Securities Exchange Act of 1934** 

**(Amendment No.1)** 

## IGM Biosciences, Inc.
**(Name of Subject Company)** 

**(Name of Persons Filing Statement)** 

**Common Stock, $0.01 par value per share** 

**(Title of Class of Securities)** 

**449585108** 

**(CUSIP Number of Class of Securities)** 

**Mary Beth Harler, M.D.** 

**Chief Executive Officer** 

**IGM Biosciences, Inc.** 

**3 East Third Avenue, Suite 200** 

**San Mateo, California 94401** 

**(650) 965-7873** 

**(Name, address, and telephone number of person authorized to receive notices and communications** 

**on behalf of the persons filing statement)** 

***With a copy to:***

**Tony Jeffries** 

**Robert T. Ishii** 

**Jennifer Knapp** 

**Ethan Lutske** 

**Wilson Sonsini Goodrich & Rosati, Professional Corporation** 

**650 Page Mill Road** 

**Palo Alto, California 94304** 

**(650) 493-9300** 

☐ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

------

This Amendment No. 1 (this "Amendment") to Schedule 14D-9 amends and supplements the Schedule 14D-9 previously filed by IGM Biosciences, Inc., a Delaware corporation ("IGM" or the "Company") with the U.S. Securities and Exchange Commission (the "SEC") on July 16, 2025 (as amended or supplemented from time to time, the "Schedule 14D-9"), with respect to the tender offer made by Concentra Biosciences, LLC, a Delaware limited liability company ("Parent"), to purchase all of the issued and outstanding shares of voting and non-voting common stock, par value $0.01 per share, of the Company (the "Shares"), for (i) $1.247 per Share in cash (the "Cash Amount") plus (ii) one non-transferable contractual contingent value right per Share (a "CVR," and each CVR together with the Cash Amount, the "Offer Price"), all upon the terms and subject to the conditions as set forth in the Offer to Purchase, dated July 16, 2025 (as amended or supplemented from time to time, the "Offer to Purchase"), and in the related Letter of Transmittal (as amended or supplemented from time to time, the "Letter of Transmittal," which, together with the Offer to Purchase, as each may be amended or supplemented from time to time, constitute the "Offer").

The Offer is described in a Tender Offer Statement filed under cover of Schedule TO with the SEC on July 16, 2025, by Parent (as may be amended or supplemented from time to time).

Capitalized terms used in this Amendment but not defined herein shall have the respective meaning given to such terms in the Schedule 14D-9. The information set forth in the Schedule 14D-9 remains unchanged and is incorporated herein by reference, except that such information is hereby amended or supplemented to the extent specifically provided herein. This Amendment is being filed to disclose certain updates as reflected below.

---

| | |
|:---|:---|
| **ITEM 8.** | **ADDITIONAL INFORMATION**  |

---

Item 8 of the Schedule 14D-9 is hereby amended and supplemented by adding, immediately after the subsection titled "- *Regulatory Approvals*," the following new subsection:

**"Final Results of the Offer and Completion of the Merger** 

The Offer and related withdrawal rights expired at one minute after 11:59 p.m., Eastern time, on August 13, 2025 and were not further extended. Broadridge Corporate Issuer Solutions, LLC, the depositary and paying agent for the Offer, advised Parent that, as of the expiration of the Offer, a total of 28,373,092 voting Shares were validly tendered and not validly withdrawn, representing approximately 77.53% of the voting Shares outstanding as of the expiration of the Offer.

As of the expiration of the Offer, the number of voting Shares validly tendered in accordance with the terms of the Offer and not validly withdrawn satisfied the Minimum Tender Condition (as defined in the Merger Agreement), and all other conditions to the Offer were satisfied or waived. Immediately after the expiration of the Offer, Parent irrevocably accepted for payment all Shares validly tendered and not validly withdrawn, and expects to promptly pay for such Shares pursuant to the terms of the Offer and the Merger Agreement.

As a result of its acceptance of the Shares tendered pursuant to the Offer and in accordance with Section 251(h) of the DGCL, Parent owns a number of Shares that is greater than the percentage of Shares that would be required to adopt the Merger Agreement by a vote of IGM's stockholders. Accordingly, pursuant to the Merger Agreement, Parent completed the acquisition of IGM on August 14, 2025 by consummating the Merger pursuant to the Merger Agreement without a vote of IGM's stockholders in accordance with Section 251(h) of the DGCL. At the Effective Time, each outstanding Share (other than (i) Shares held in the treasury of IGM immediately prior to the Effective Time, which will be canceled without any conversion thereof and no consideration will be delivered in exchange therefor, (ii) any Shares held by stockholders or owned by beneficial owners who are entitled to demand, and have properly demanded, appraisal of such Shares in accordance with the DGCL, and have neither failed to perfect nor effectively withdrawn or lost such rights prior to the Effective Time and (iii) Shares that were owned by Parent, Merger Sub or any other subsidiary of Parent at the commencement of the Offer and is owned by Parent, Merger Sub or any other subsidiary of Parent immediately prior to the Effective Time) was cancelled and converted into the right to receive the Offer Price, without interest and in each case, less any applicable withholding taxes, from Parent.

Prior to the opening of trading on the Nasdaq Stock Market LLC ("Nasdaq") on August 14, 2025, all Shares ceased trading, and following the consummation of the Merger, all Shares will be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934, as amended."

------

**SIGNATURE** 

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: August 14, 2025

---

| | |
|:---|:---|
| **IGM Biosciences, Inc.** | **IGM Biosciences, Inc.** |
| By: | /s/ Mary Beth Harler, M.D. |
|  | Mary Beth Harler, M.D. |
|  | Chief Executive Officer |

---